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Introduction
• >80% of urinary tract infections (UTIs) caused by 
Escherichia coli (E. coli) (Nicolle, 2008)
• Community acquired (CA) or hospital acquired (HA)
classification
• Standard treatment is antibiotics (Stuck et al., 2012)
• Treatment based on local susceptibility patterns (Teoh et al., 2013)
• Inappropriate treatment leads to emergence of resistant 
pathogens & recurrence of infection (Trautner, 2010)
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Introduction
• Evidence shows urinary E. coli is becoming increasingly 
resistant to common antimicrobials (WHO, 2014)
• Whilst prevalence rates for urinary E. coli resistance have 
been reported in Australia, available data do not adjust for 
age & sex
• To our knowledge there are no data comparing resistance 
patterns for CA and HA UTIs
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Aims
 To describe the antimicrobial resistance patterns of        
E. coli UTI over five years (2009-2013) in patients at the 
Canberra Hospital 
 Compare the prevalence of resistance in community-
acquired and hospital-acquired E. coli UTI
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Significance
• Expand understanding of antimicrobial resistance in 
urinary E. coli infections in Australia
• Contribute to ongoing surveillance data in the Australian 
Capital Territory (ACT)
• Potential for study findings to inform treatment decisions 
for UTI  & influence therapy based on site of acquisition
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Methods
• Ethics approval granted by ACT Health and ACU HREC
• Cross-sectional design
• Inclusions: Canberra Hospital samples; E. coli growth of 
≥107 cfu/L 
• CA UTI: within 48 hours of admission; outpatients 
• HA UTI: more than 48 hours after admission or within 48 
hours of discharge
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Methods
• Only the first positive E. coli culture per patient per year 
was included in analysis
• Overall 5-year and yearly antimicrobial resistance rates 
were calculated 
• Rates compared between CA and HA UTIs
• Prevalence of Extended Spectrum Beta Lactamase (ESBL) 
producing E.coli
• Crude and adjusted time series analyses were conducted 
to assess resistance trends over the 5-year study period
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Results
• 5346 positive E. coli UTIs belonging to 4744 patients
– CA UTI 84.3% (n=4505) 
– HA UTI 15.7% (n=841)
• Mean age of all patients was 57.0 years (SD=27.6)
• 80.3% (n=3806) of patients were women
• Resistance highest for ampicillin (41.9%) & trimethoprim-
sulphamethoxazole (32.7%)
• Resistance lowest for meropenem (0.1%) & gentamicin 
(4.0%)
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Antimicrobial 5-year resistance %
Ampicillin 41.9
Trimethoprim-sulphamethoxazole 32.7
Trimethoprim 20.7
Norfloxacin 16.2
Ceftriaxone 13.5
Cephazolin 10.6
Piperacillin-tazobactam 10.3
Nalidixic acid 8.4
Nitrofurantoin 7.8
Amoxycillin-clavulanic acid 6.7
Ciprofloxacin 6.5
Gentamicin 4.0
Meropenem 0.1
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Results
• Significantly higher resistance (P<0.05) in HA compared to 
CA UTI for: 
amoxycillin-clavulanate
cephazolin
gentamicin 
piperacillin-tazobactam 
• ESBL-producing E. coli significantly higher (P=0.01) in HA 
(3.0%; n=25) compared with CA UTI (1.7%; n=75)
11
Results
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Results
• Significant increase in resistance trend noted for all five 
antimicrobials (P<0.05)
• Seasonal resistance pattern only significant for 
Trimethoprim (P=0.0056)
• Regression analysis indicated a possible association 
between ciprofloxacin resistance and trimethoprim-
sulphamethoxazole resistance with older age
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Discussion
• Resistance rates lower than reported for single site 
studies in other countries (Ma et al., 2012; Perrin et al. 1999)
• High levels of ampicillin and trimethoprim-
sulphamethoxazole resistance question their use as 
suitable empirical agents in the management of UTI in 
this population
• Differences in resistance for HA and CA UTI comparable 
with findings reported previously (Ma et al., 2012)
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Discussion
• Presence of ESBL-producing E. coli in both HA and CA UTI 
pose significant public health concern
• Evidence to support findings of increase in resistance 
over time
• Seasonal trimethoprim resistance should be explored 
further 
• Association between increasing age and antimicrobial 
resistance consistent with published literature (Blaettler et al. 2009)
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Implications and Conclusion
• While resistance rates are lower than other studies, there 
is need for continuous resistance surveillance in the ACT
• Amoxycillin-clavulanate and nitrofurantoin still effective 
in this population
• Study findings will help inform UTI treatment guidelines
• Also provide baseline resistance data for future 
comparison and inform future interventions that can be 
evaluated
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